Chemistry:Lu AE04621
From HandWiki
| Clinical data | |
|---|---|
| Other names | Lu-AE04621; Lu AE 04621; LuAE04621 |
| Routes of administration | Oral[1] |
| Drug class | Dopamine receptor agonist; Dopamine D1 and D2 receptor agonist |
| ATC code |
|
Lu AE04621 is a dopamine receptor agonist which is or was under development for the treatment of Parkinson's disease but has not been marketed.[1][2][3] It is taken orally.[1] The drug is said to be a prodrug of the catecholamine Lu AA40326 and to act as a dual dopamine D1 and D2 receptor agonist.[1][2][3][4] Lu AE04621 is or was under development by Lundbeck.[1][2] As of November 2023, it is in phase 1 clinical trials and has been since at least 2016, but no recent development has been reported since February 2019.[1] The chemical structure of Lu AE04621 has not yet been disclosed.[1][2][3] However, it may be a prodrug of 5,6-diOH-DPAT or a related approach.[2]
See also
- List of investigational Parkinson's disease drugs
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Lu AE 04621". 5 November 2023. https://adisinsight.springer.com/drugs/800031909.
- ↑ 2.0 2.1 2.2 2.3 2.4 "Current approaches to the treatment of Parkinson's Disease". Bioorganic & Medicinal Chemistry Letters 27 (18): 4247–4255. September 2017. doi:10.1016/j.bmcl.2017.07.075. PMID 28869077.
- ↑ 3.0 3.1 3.2 "Recent advances in dopaminergic strategies for the treatment of Parkinson's disease". Acta Pharmacologica Sinica 41 (4): 471–482. April 2020. doi:10.1038/s41401-020-0365-y. PMID 32112042.
- ↑ Clinical trial number NCT02649608 for "An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients" at ClinicalTrials.gov
 |  |
